580
Participants
Start Date
December 31, 2014
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
DSP-5423P Placebo
DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
DSP-5423P 40mg
DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
DSP-5423P 80mg
DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
DSP-5423P Placebo-to-Flex
"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
DSP-5423P Active-to-Flex
"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
3 Sites, Beijing, Etc.
53 Sites, Tokyo Etc.
14 Sites, Kuala Lumpur, Etc.
9 Sites, Manila, Etc.
8 Sites, Smolensk, Etc
7 Sites, Seoul, Etc.
6 Sites, Taipei, Etc.
8 Sites, Poltava, Etc
Sumitomo Pharma Co., Ltd.
INDUSTRY